Belgium Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2022 to 2030

Belgium ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Belgium's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-2030 due to factors like rising cases of ADHD among the Belgian population and the improved health expenditure for greater access to ADHD medications. The Belgium ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major players in the market include Celyad, Confo Therapeutics, and Advanz Pharmaceuticals.

ID: IN10BEPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Parul Choudhary

Buy Now

Belgium Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Belgium Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $65 Mn in 2022 and is projected to reach $116 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. In order to cover higher utility bills, the hospital industry in Belgium will receive $85.43 Mn in the first half of 2023. One of the budgetary measures will release $106.79 Mn as structural cost compensation for conventional healthcare providers—those who adhere to the formal fees set by physicians and healthcare organizations in Belgium. $106.79 Mn will be made available from the health insurance budget, which was unanimously passed, for structural cost compensation for healthcare providers, but only for those who are contracted. The highest co-payment ceilings will also not be indexed. Additional funding for accessible dental care, improved eyewear coverage, and targeted initiatives to improve treatment and quality of life for cancer patients are also planned.

The neurological condition known as Attention Deficit Hyperactivity Disorder (ADHD) is frequently affected by genetics. It is marked by impulsivity, restlessness, or hyperactivity. In the setting of primary care, it is the neurodevelopmental disorder with a childhood onset that is most commonly encountered. Most often, symptoms appear before the age of seven. According to a study by the Belgian Health Care Knowledge Centre (KCE) that was released in 2022, children and adolescents in Belgium between the ages of 6 and 17 are thought to have an ADHD prevalence of about 5.5%. No matter the patient's age, the High Council for Health (SHC) in Belgium emphasizes that the first course of treatment should be psycho-educative therapy, which also involves the patient's family and community. Other approaches should only be contemplated when that fails. Methylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age of 18. Adults are not at all reimbursed by typical medical insurance. Non-drug therapies are either not adequately accessible in Belgium or are too expensive for many families to afford due to cost-reimbursement policies.

belgium attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

As the prevalence of ADHD rises and more people in Belgium are given the diagnosis, there is increasing demand for ADHD treatments like medication and psychotherapy. To more accurately identify and treat ADHD, breakthroughs in technology are being developed. As healthcare expenditure in Belgium rises, more funds are being directed toward ADHD treatment. This is anticipated to drive the Belgium ADHD therapeutics market's expansion.

Market Restraints

Financial hardships or resource limitations may make it more challenging for patients to receive treatment for ADHD. This may restrict the Belgium ADHD therapeutics market expansion. Some patients may experience negative side effects from their ADHD therapies, which may cause them to discontinue taking it or reduce their desire to take it. This might slow the Belgium ADHD therapeutics market's expansion.

Competitive Landscape

Key Players

AgomAb Therapeutics (BEL)
Biotalys (BEL)
Bone Therapeutics (BEL)
Celyad (BEL)
Confo Therapeutics (BEL)
Advanz Pharmaceutical
Highland Therapeutics
NEOS Therapeutics
Janssen Pharmaceuticals
Pfizer

Healthcare Policies and Regulatory Landscape

The Federal Agency for Medicines and Health Products, formerly the Directorate-General for Medicinal Products of the FPS Public Health (Agence Federerale des Medicaments et des Produits de Sante, FAMHP), was established in January 2007 and serves as Belgium's official agency for licensing pharmaceuticals and health products. The agency's goal is to guarantee the efficacy, safety, and quality of drugs and other medical supplies both during the clinical research process and once they hit the market. Moreover, it is in charge of approving the initial national marketing application for a medicinal product in accordance with the national, decentralized, and mutual acknowledgment procedures outlined in the Royal Decree of December 12, 2006. No drug may be marketed in Belgium without licensing or marketing authorization. On the basis of the applicant's scientific data, the experts chosen by the various authorities assess the drug's quality, safety, and effectiveness. They depend on European-level scientific standards for this assessment. Only products with clear evidence of their quality, safety, and efficacy are authorized for marketing as drugs. The same scientific criteria for quality, safety, and effectiveness must be met by all medications approved for marketing, whether they are trademarked or generic.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.